'Skyrocketing' Drug Prices, Access And Availability In Line For EU Scrutiny
This article was originally published in SRA
Executive Summary
The European Commission is to conduct an analysis of the impact of incentives such as data exclusivity, market exclusivity and patent term extensions on innovation, drug pricing, and access to medicines, including generics. The move was requested by member state health ministers who say they are concerned about cases of 'very high and unsustainable price levels' hindering patient access to effective and affordable medicines.